Six pediatric B-ALL patients were treated with pembrolizumab to augment response to CD19-specific CAR-T cells and three patients showed clinical responses with prolonged persistence of CAR-T cells [46]. Here, CD19 is linked to precursor B-cell acute lymphoblastic leukemia.